A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations

Trial Information

Start DateSeptember 2021
End DateTBD
Trial Duration52 Weeks
Number of Visits~23
Lead CRCSuzanne Fleming
StatusIn Start-Up

For additional information
on this trial contact: